603229.SH
奥翔药业
SSE · Healthcare · Biotechnology · CN
CNY 7.94
−1.98%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 794.8M | 792.8M | 795.3M | 816.8M | 764.5M |
| Cost of Revenue | 365.1M | 368.6M | 364.0M | 367.2M | 370.8M |
| Gross Profit | 429.7M | 424.2M | 431.3M | 449.6M | 393.8M |
| Operating Expenses | |||||
| R&D Expense | 170.3M | 167.9M | 100.4M | 78.1M | 67.1M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 98.6M | 97.7M | 106.5M | 100.3M | 93.8M |
| Selling & Marketing Expense | 20.4M | 20.2M | 16.8M | 18.1M | 20.8M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 329.5M | 302.0M | 211.5M | 169.4M | 142.9M |
| Cost and Expenses | 694.6M | 670.5M | 575.5M | 536.5M | 513.7M |
| Operating Income (EBIT) | 110.6M | 140.0M | 241.1M | 290.8M | 257.7M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 108.5M | 137.9M | 240.2M | 290.8M | 255.9M |
| Income Tax Expense | 468.6K | 7.3M | 33.4M | 36.9M | 20.5M |
| Bottom Line | |||||
| Net Income | 108.0M | 130.6M | 206.8M | 253.9M | 235.4M |
| Earnings from Cont. Ops | 108.0M | 130.6M | 206.8M | 253.9M | 235.4M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 108.0M | 130.6M | 206.8M | 253.9M | 235.4M |
| Per Share | |||||
| Basic EPS | CN¥0.13 | CN¥0.16 | CN¥0.25 | CN¥0.31 | CN¥0.41 |
| Diluted EPS | CN¥0.13 | CN¥0.16 | CN¥0.25 | CN¥0.31 | CN¥0.41 |
| Revenue Per Share | CN¥0.99 | CN¥0.97 | CN¥0.96 | CN¥1.00 | CN¥1.33 |
| Shares | |||||
| Basic Shares Outstanding | 805.5M | 816.1M | 827.2M | 819.0M | 574.1M |
| Diluted Shares Outstanding | 805.5M | 816.1M | 827.2M | 819.0M | 574.1M |
| Profitability Metrics | |||||
| EBITDA | — | 214.2M | 304.8M | 331.4M | 292.2M |
| D&A | — | 74.2M | 63.7M | 40.6M | 34.5M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026